Please assess the completion status of the following clinical trial:

Trial Title: Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight \>=5kg~* Plasmodium falciparum infection with parasite density \> 2000/µL~* Fever or history of fever~* Able to be treated by oral route~* No signs of severe malaria~* No known allergy to study drugs~* No other severe illnesses or underlying diseases~* No known pregnancy or negative urinary pregnancy test for women of child bearing age~* No participation in another ongoing clinical study~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate + Amodiaquine (Type: EXPERIMENTAL): Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: \>= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).